CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection

Pampusch, M. S., Abdelaal, H. M., Cartwright, E. K., Molden, J. S., Davey, B. C., Sauve, J. D., Sevcik, E. N., Rendahl, A. K., Rakasz, E. G., Connick, E., Berger, E. A. and Skinner, P. J. CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLOS Pathogens. 2022; 18(2), e1009831. doi: 10.1371/journal.ppat.1009831

Date

BioLife Solutions Symbol

This website uses cookies to ensure you get the best experience on our website.